Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

Y0000196

Ondansetron for TLC system suitability

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Ondansetron hydrochloride dihydrate, 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one hydrochloride, GR 38032F

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C18H19N3O · HCl · 2H2O
Numero CAS:
103639-04-9
Peso molecolare:
365.85
Numero MDL:
MFCD00374371
Codice UNSPSC:
41116107
ID PubChem:
329830878
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

ondansetron

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

Cl[H].[H]O[H].[H]O[H].Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C

InChI

1S/C18H19N3O.ClH.2H2O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2;;;/h3-6,9-10,13H,7-8,11H2,1-2H3;1H;2*1H2
VRSLTNZJOUZKLX-UHFFFAOYSA-N

Informazioni sul gene

human ... HTR3A(3359)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Ondansetron for TLC system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

5-HT3 serotonin receptor antagonist

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

PHR1141

Ondansetron Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

1478618

Ondansetron Related Compound C, United States Pharmacopeia (USP) Reference Standard

1478593

Ondansetron Related Compound A, United States Pharmacopeia (USP) Reference Standard

1478629

Ondansetron Related Compound D, United States Pharmacopeia (USP) Reference Standard

1478582

Ondansetron hydrochloride, United States Pharmacopeia (USP) Reference Standard

1478630

Ondansetron Resolution Mixture, United States Pharmacopeia (USP) Reference Standard

PHR1181

2-Methylimidazole (Ondansetron Impurity F), Pharmaceutical Secondary Standard; Certified Reference Material

Y0000195

Ondansetron impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000197

Ondansetron for LC system suitability, European Pharmacopoeia (EP) Reference Standard

Y0000218

Ondansetron hydrochloride dihydrate, European Pharmacopoeia (EP) Reference Standard

Y0001326

Imidazolo, European Pharmacopoeia (EP) Reference Standard

Y0001320

Ondansetron impurity F, European Pharmacopoeia (EP) Reference Standard

Y0001345

Ondansetron impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001346

Ondansetron impurity G, European Pharmacopoeia (EP) Reference Standard

1478571

Ondansetron, United States Pharmacopeia (USP) Reference Standard

BP808

Ondansetron hydrochloride dihydrate, British Pharmacopoeia (BP) Reference Standard

BP806

Ondansetron impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR2224

Ondansetron Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2223

Ondansetron Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2221

Ondansetron Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

Avvertenze

Danger

Indicazioni di pericolo

H301,H318,H410

Classi di pericolo

Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 2 - Eye Dam. 1

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Choose from one of the most recent versions:

Certificati d'analisi (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Ali Mujtaba et al.
Drug testing and analysis, 5(2), 122-125 (2013-02-16)
A new, simple, rapid, accurate and precise high performance thin layer chromatography (HPTLC) method has been developed for the estimation of ondansetron hydrochloride in bulk and sublingual tablets. The mobile phase composition was chloroform : ethyl acetate : methanol :
Björn Pasternak et al.
The New England journal of medicine, 368(9), 814-823 (2013-03-01)
Ondansetron is frequently used to treat nausea and vomiting during pregnancy, but the safety of this drug for the fetus has not been well studied. We investigated the risk of adverse fetal outcomes associated with ondansetron administered during pregnancy. From
Roger M Browning et al.
Regional anesthesia and pain medicine, 38(1), 39-43 (2012-10-30)
Cesarean delivery is commonly performed under regional anesthesia, which is often associated with maternal shivering. This can cause distress and interfere with monitoring. The study objective was to evaluate the antishivering efficacy of ondansetron, which reduces the incidence and severity
Ioannis Goutos
Journal of burn care & research : official publication of the American Burn Association, 34(1), 82-93 (2012-11-09)
Pruritus in burn wounds is a common symptom affecting patient rehabilitation. Over the last decades, there has been a resurgence of interest into more effective strategies to combat this distressing problem; nevertheless, no reports exist in the literature to propose
Daniel R Gomez et al.
Cancer, 119(7), 1428-1436 (2012-12-06)
Nausea and vomiting (N/V) during chemotherapy can have profound clinical and economic consequences. Effective antiemetic agents are available for prophylaxis, but barriers may prevent their use. For this population-based study, the authors assessed the rates of antiemetic prophylaxis use, and
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.